Catherine Alix Panabieres | Director, Laboratory Of Rare Human Circulating Cells
Institut Univ de Recherche Clinique

Catherine Alix Panabieres, Director, Laboratory Of Rare Human Circulating Cells, Institut Univ de Recherche Clinique

Dr Catherine Alix-Panabières received her PhD degree in 1998 at the Institute of Virology, University Louis Pasteur, in Strasbourg in France. In 1999, she moved to Montpellier where she did a postdoctoral research at the University Medical Centre. During this last decade, Dr Alix-Panabières has focused on optimizing new techniques of enrichment, detection and characterization of viable circulating tumor cells (CTCs) in patients with solid tumors. She is the expert for the EPISPOT technology that is used to detect viable CTCs in patients with breast, prostate, colon, head & neck cancer and melanoma. This technology has been recently improved to detect functional CTCs at the single cell level (EPIDROP). Dr Catherine Alix-Panabières & Prof Pantel coined for the first time the term ‘Liquid Biopsy’ in 2010 (Trends Mol Med).   In 2010, she achieved getting a permanent position at the Hospital and at the Faculty of Medicine of Montpellier (MCU-PH). As an associate professor, she became the new director of the Laboratory of Rare Human Circulating Cells (LCCRH). In this unique platform LCCRH, they isolate, detect and characterize CTCs using combinations many technologies. She has authored or co-authored >110 scientific publications in this field during the last years and 12 book chapters, she is the inventor of three patents in the liquid biopsy field and she is part of French national projects: for ex, PANTHER (FUI project), STIC-METABREAST, TACTIK (PHRC), MECA-CTC (ITMO) as well as of big European projects: CTC-SCAN (Transcan project), CANCER-ID (IMI project), PROLIPSY (Transcan project) and European Liquid Biopsy Academy (ELBA, Marie-Curie project). Moreover, Catherine Alix-Panabières is an active member involved in the European Liquid Biopsy Society (ELBS - www.elbs.eu).

Appearances:



BioData World Congress Day 1 @ 14:20

Clinical Implementation of Liquid Biopsy- Challenges to adoption and Roll Out

BioData World Congress Day 1 @ 16:00

Circulating Tumor Cells as Liquid Biopsy: From Discovery to Clinical Application

  • How to detect and analyze single viable CTCs?
  • Clinical relevance of CTCs: the example of PD-L1 in Onco-immunology
  • Challenges to establish CTC lines from metastasis-competent CTCs in colon cancer
last published: 21/Sep/21 15:25 GMT
last published: 21/Sep/21 15:25 GMT

back to speakers

GET INVOLVED AT BIODATA WORLD CONGRESS

 

 

TO SPONSOR


Alistair Wilmot
alistair.wilmot@terrapinn.com
0207 092 1174

 

 

TO SPEAK


Edward Glanville

edward.glanville@terrapinn.com
0207 092 1042

 

 

MARKETING OPPORTUNITIES


Onika Akhtar
onika.akhtar@terrapinn.com
0207 092 1034